PHIBRO ANIMAL HEALTH CORP — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Daniel M. Bendheim (President/CEO) and Glenn C. David (CFO) certified on November 4, 2026, that the 10-Q fairly presents Phibro's financial condition and results. Both officers affirmed disclosure controls and internal controls over financial reporting are effective, with no significant deficiencies, material weaknesses, or fraud identified in the most recent quarter.
Why this rating
Standard Sarbanes-Oxley certification language; routine quarterly filing requirement with no disclosed control issues, changes, or material adverse findings.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.